Cephradine

Brands of Cephradine ( Cefradine ) in Kenya

Cefracef® ,Nirpo JMI Pharma Ltd
Intracef®, Beximco


Cefradine / Cephradine in Kenya : Price, Brand names, Uses, Indications
Cefradine / Cephradine Chemical Structure

Mechanism of Action:

Cephradine disrupts the synthesis of the peptidoglycan layer forming the bacterial cell wall. The peptidoglycan layer is important for cell wall structural integrity.

INDICATIONS:

  • Respiratory tract infections (such as tonsillitis, pharyngitis, and lobar pneumonia) caused by group A beta-hemolytic streptococci and S. pneumoniae (formerly D. pneumonia).
  • Otitis media caused by group A beta-hemolytic streptococci, S. pneumoniae, H. influenzae, and staphylococci.
  • Skin and skin structure infections caused by staphylococci (penicillin-susceptible and penicillin-resistant) and beta-hemolytic streptococci.
  • Urinary tract infections, including prostatitis, caused by E. coli, P. mirabilis and Klebsiella species.

DOSAGE AND ADMINISTRATION

Adults

Respiratory tract infections and skin and soft tissue infections – the usual dose is 250mg or 500mg four times daily or 500mg or 1g twice daily depending on the severity and site of infection.

Urinary tract infections – the usual dose is 500mg four times daily or 1g twice daily. This may need to be increased for severe or chronic infections. Prolonged intensive therapy is needed for complications such as prostatitis and epididymitis.

Elderly

As for adults. Patients with impaired renal or hepatic function should be monitored as modifications of the dosage schedule may be required.

Paediatric population

The usual dose is 25 to 50 mg/kg/day total, given in two or four equally divided doses. For otitis media daily doses from 75 to 100mg/kg in divided doses every 6 to 12 hours are recommended. Maximum dose 4g per day.

Cefradine may be taken without regard to meals.

All patients irrespective of age and weight: In the case of severe or chronic infection larger doses of up to 1g four times daily may be given. Administration should be continued for a minimum of 48-72 hours after the patient becomes asymptomatic or evidence of bacterial eradication has been obtained.

CONTRAINDICATIONS

Cephradine is contraindicated in patients with known allergy to the cephalosporin class of antibiotics.

DRUG INTERACTIONS

Loop diuretics may increase nephrotoxicity of cephalosporins.

Probenecid has been seen to raise serum concentrations of cefradine, by reducing renal clearance of the cephalosporins.

There is evidence of partial allergenicity between the penicillins and the cephalosporins. Therefore, cefradine should be used with caution in those patients with known hypersensitivity to penicillins. There have been instances of patients who have had reactions to both drug classes (including anaphylaxis).

ADVERSE EFFECTS

Infections and infestations

Rarely: Antibiotic-associated colitis
Frequency unknown: Vaginitis, candidal overgrowth, candidiasis

Blood and lymphatic system disorders

Frequency unknown:Eosinophilia, blood disorders (including thrombocytopenia, leucopenia, agranulocytosis, aplastic anaemia and haemolytic anaemia)

Immune system disorders

Frequency unknown: Fever, athralgia, serum sickness-like reactions, anaphylaxis

Psychiatric disorders

Frequency unknown: Confusion, sleep disturbances

Nervous system disorders

Frequency unknown: Hypersensitivity, hyperactivity, hypertonia, dizziness, nervousness

Rarely: Headache

Gastrointestinal disorders

Frequency unknown: Diarrhoea, nausea, glossitis, heartburn

Rarely:Vomiting, abdominal discomfort,
Hepatobiliary disorders

Frequency unknown: Liver, enzyme disturbances, transient hepatitis, cholestatic jaundice

Skin and subcutaneous tissue disorders

Frequency unknown: Rashes, toxic epidermal necrolysis, pruritis, urticaria, erythema multiforme, Stevens-Johnson syndrome, oedema

Renal and urinary disorders

Frequency unknown: Reversible interstitial nephritis

General disorders and administration site conditions

Frequency unknown:Tightness in the chest

Investigations

Frequency unknown: Elevation of blood urea nitrogen, serum creatinine, alanine aminotransferase, aspartate aminotransferase, total bilirubin, alkaline phosphates, positive direct Coombs’ test

Musculoskeletal and connective tissue disorder

Frequency unknown: joint pain

Reporting of suspected adverse reactions:

The PPB Department of Pharmacovigilance was set up with a vision to develop, implement and continuously upgrade an appropriate system for detecting, reporting, and monitoring adverse drug reactions (ADRs) and other relevant problems with medicines in Kenya. The department strives to ensure the safety and efficacy of pharmaceutical products in Kenya.
Reporting suspected adverse reactions after authorization of the medicinal product are important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals/ Patients are encouraged to report any suspected adverse reactions via Pharmacovigilance Yellow Form, pv@pharmacyboardkenya.org or clicking below button:


Cephradine in Kenya
Cephradine in Kenya
Cephradine in Kenya
Cephradine in Kenya
Cephradine in Kenya

Clinical | Pharmacokinetic data


Pregnancy Category: B
Routes of Administration: Oral, IM, IV
Bioavailability: Well absorbed
Protein Binding: Not Available
Metabolosim: Nil
Onset of Action: Not Available
Elimination Half life: 0.9 hours
Excretion: Renal, unchanged

Legal Status | Dosage forms & Strengths


Prescription Category:
(Prescription only)
Narcotic Drugs and Psychotropic Substances (Control ) Act Schedule:
This drug is not a controlled substance under Narcotic Drugs and Psychotropic Substances (Control ) Act
Dosage Forms | Strengths:


Drug Indentifiers:

CAS Number
PubChemCID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard


Drug Images

References/ Citation:

  • PPB Drugs Retention Register
  • Klastersky, J., D. Daneau, and Daniele Weerts. “Cephradine.” Chemotherapy 18.3 (1973): 191-204.
  • Finkelstein, E., et al. “Pharmacokinetics of oral cephalosporins: cephradine and cephalexin.” Journal of Pharmaceutical Sciences 67.10 (1978): 1447-1450.
  • Dolfini JE, Applegate HE, Bach G, Basch H, Bernstein J, Schwartz J, Weisenborn FL (February 1971). “A new class of semisynthetic penicillins and cephalosporins derived from D-2-(1,4-cyclohexadienyl)glycine”. Journal of Medicinal Chemistry. 14 (2): 117–9. doi:10.1021/jm00284a008



What was the patient being treated for
%d bloggers like this: